MiMARK Diagnostics

📍 Barcelona, Spain🗓 Founded 2021👥 26 employees💰 Last funded Nov 2021
Biotechnology Research🌐 mimark.es
Website LinkedIn
In MiMARK, we care for womens health. We are specialized in the discovery, verification and validation of biomarkers to develop new solutions for gynecological patients. Abnormal uterine bleeding affects 14M between women in EU and US yearly (in women between 50 and 75 years old). Diagnosis of endometrial cancer is mandatory for all those women as 10% of those will be diagnosed with the disease. Current diagnosis is based on the pathological examination of an endometrial biopsy (pipelle biopsy), but this fails to diagnose in up to 30% of patients, and provides an inaccurate diagnosis in up to 55% of cases. This failure is associated to the scarce cellularity of the sample. In those cases, invasive diagnosis using histeroscopy needs to be performed. Our solution: WomEC. It is an in vitro diagnostic tool based on the determination of 5 protein biomarkers in uterine fluid samples to provide diagnosis to 100% of patients, rule out endometrial cancer with great specificity, and provide information on histological subtype of the tumor to guide surgical treatment.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2021
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
France
1
Frequently asked questions
Who invested in MiMARK Diagnostics?
MiMARK Diagnostics has 1 investors on record on gritt.io, including 1 early-stage backers.
When did MiMARK Diagnostics last raise funding?
The most recent investment in MiMARK Diagnostics recorded on gritt.io was in November 2021.
When was MiMARK Diagnostics founded?
MiMARK Diagnostics was founded in 2021.
What industry is MiMARK Diagnostics in?
MiMARK Diagnostics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is MiMARK Diagnostics based?
MiMARK Diagnostics is headquartered in Barcelona, Spain.